Quantum Effects of Electromagnetic Fields Stimulation on Intrinsically Disordered Proteins and Their Role in Aging, Proteostasis, and Neurodegeneration

Electromagnetic field stimulation (EMFS) has emerged as a promising modality for regulating the structural dynamics of biological macromolecules implicated in aging and neurodegenerative disorders. In particular, EMFS can alter the conformation of abnor-mally folded proteins, such as amyloid-β (Aβ) peptides and their aggregates, thereby mitigating pathological protein aggregation and delaying neurodegeneration. The molecular interactions at play are governed by quantum mechanical forces acting on interfacial water molecules adjacent to hydrophilic protein surfaces. These interactions modulate the structural and functional dynamics of key proteins implicated in aging and neurodegeneration, including Heat Shock Factor 1 (HSF1) and amyloid-beta (Aβ). This study advances the mechanistic understanding of water-mediated quantum effects, analogous to those observed in enzyme catalysis, highlighting the role of proton tunneling within extensive hydrogen-bond networks. These phenomena are especially prevalent in intrinsically disordered proteins (IDPs), which are central to proteostasis(definition) and highly susceptible to structural perturbations that lead to post-translational modifications associated with aging and neurodegeneration. We propose repeated electromagnetic field stimulation (REMFS) as a novel thera-peutic strategy to restore the native conformational states of critical IDPs, including Aβ, α-synuclein, and Tau. Furthermore, REMFS appears to reverse the age-related post-translational modifications of key proteostasis regulators, such as HSF1 and other heat shock proteins. Through quantum-mechanical modulation, REMFS influences multiple Alzheimer’s disease (AD) pathways, demonstrating the potential to prevent or reverse pathological changes in cellular and organismal models. These findings support the further development of REMFS as an anti-amyloid and anti-aggregation therapy for AD and related neurodegenerative conditions.